Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | disease | BEFREE | Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis. | 30639623 | 2019 | ||||
|
0.080 | Biomarker | disease | BEFREE | Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis. | 28622623 | 2017 | ||||
|
0.080 | Biomarker | disease | BEFREE | Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis (MF). | 27889820 | 2017 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Currently, clinical studies testing various JAK2-inhibitors in PV, ET as well as in primary and secondary myelofibrosis (MF) are under way. | 21062242 | 2011 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | In conclusion, constitutive heterozygous expression of JAK2(V617F) in mice is not embryo-lethal but results in severe PV-like disease with secondary myelofibrosis and not in ET-like disease as expected from patient study. | 20472827 | 2010 | ||||
|
0.080 | Biomarker | disease | BEFREE | JAK2 617V>F homozygosity associated with more frequent evolution into secondary myelofibrosis in both PV and ET. | 17379742 | 2007 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. | 16418333 | 2006 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | The clinical and pathological data on JAK2 V617F-positive MPD patients suggest that the JAK2 V617F mutation defines one disease entity with several sequential steps of ET, PV, and secondary myelofibrosis during long-term follow-up, and that the wild-type JAK2 MPDs may represent another distinct entity with a related but different molecular etiology. | 16810609 | 2006 |